Cargando…

Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK

AIM: To investigate the anti-inflammatory effect and the possible mechanisms of an agonist of cannabinoid (CB) receptors, WIN55-212-2 (WIN55), in mice with experimental colitis, so as to supply experimental evidence for its clinical use in future. METHODS: We established the colitis model in C57BL/6...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Ya-Jing, Li, Yong-Yu, Lin, Xu-Hong, Li, Kun, Cao, Ming-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116595/
https://www.ncbi.nlm.nih.gov/pubmed/27920472
http://dx.doi.org/10.3748/wjg.v22.i43.9515
_version_ 1782468689318117376
author Feng, Ya-Jing
Li, Yong-Yu
Lin, Xu-Hong
Li, Kun
Cao, Ming-Hua
author_facet Feng, Ya-Jing
Li, Yong-Yu
Lin, Xu-Hong
Li, Kun
Cao, Ming-Hua
author_sort Feng, Ya-Jing
collection PubMed
description AIM: To investigate the anti-inflammatory effect and the possible mechanisms of an agonist of cannabinoid (CB) receptors, WIN55-212-2 (WIN55), in mice with experimental colitis, so as to supply experimental evidence for its clinical use in future. METHODS: We established the colitis model in C57BL/6 mice by replacing the animals’ water supply with 4% dextran sulfate sodium (DSS) for 7 consecutive days. A colitis scoring system was used to evaluate the severity of colon local lesion. The plasma levels of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), and the myeloperoxidase (MPO) activity in colon tissue were measured. The expressions of cannabinoid receptors, claudin-1 protein, p38 mitogen-activated protein kinase (p38MAPK) and its phosphorylated form (p-p38) in colon tissue were determined by immunohistochemistry and Western blot. In addition, the effect of SB203580 (SB), an inhibitor of p38, was investigated in parallel experiments, and the data were compared with those from intervention groups of WIN55 and SB alone or used together. RESULTS: The results demonstrated that WIN55 or SB treatment alone or together improved the pathological changes in mice with DSS colitis, decreased the plasma levels of TNF-α, and IL-6, and MPO activity in colon. The enhanced expression of claudin-1 and the inhibited expression of p-p38 in colon tissues were found in the WIN55-treated group. Besides, the expression of CB1 and CB2 receptors was enhanced in the colon after the induction of DSS colitis, but reduced when p38MAPK was inhibited. CONCLUSION: These results confirmed the anti-inflammatory effect and protective role of WIN55 on the mice with experimental colitis, and revealed that this agent exercises its action at least partially by inhibiting p38MAPK. Furthermore, the results showed that SB203580, affected the expression of CB1 and CB2 receptors in the mouse colon, suggesting a close linkage and cross-talk between the p38MAPK signaling pathway and the endogenous CB system.
format Online
Article
Text
id pubmed-5116595
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-51165952016-12-05 Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK Feng, Ya-Jing Li, Yong-Yu Lin, Xu-Hong Li, Kun Cao, Ming-Hua World J Gastroenterol Basic Study AIM: To investigate the anti-inflammatory effect and the possible mechanisms of an agonist of cannabinoid (CB) receptors, WIN55-212-2 (WIN55), in mice with experimental colitis, so as to supply experimental evidence for its clinical use in future. METHODS: We established the colitis model in C57BL/6 mice by replacing the animals’ water supply with 4% dextran sulfate sodium (DSS) for 7 consecutive days. A colitis scoring system was used to evaluate the severity of colon local lesion. The plasma levels of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), and the myeloperoxidase (MPO) activity in colon tissue were measured. The expressions of cannabinoid receptors, claudin-1 protein, p38 mitogen-activated protein kinase (p38MAPK) and its phosphorylated form (p-p38) in colon tissue were determined by immunohistochemistry and Western blot. In addition, the effect of SB203580 (SB), an inhibitor of p38, was investigated in parallel experiments, and the data were compared with those from intervention groups of WIN55 and SB alone or used together. RESULTS: The results demonstrated that WIN55 or SB treatment alone or together improved the pathological changes in mice with DSS colitis, decreased the plasma levels of TNF-α, and IL-6, and MPO activity in colon. The enhanced expression of claudin-1 and the inhibited expression of p-p38 in colon tissues were found in the WIN55-treated group. Besides, the expression of CB1 and CB2 receptors was enhanced in the colon after the induction of DSS colitis, but reduced when p38MAPK was inhibited. CONCLUSION: These results confirmed the anti-inflammatory effect and protective role of WIN55 on the mice with experimental colitis, and revealed that this agent exercises its action at least partially by inhibiting p38MAPK. Furthermore, the results showed that SB203580, affected the expression of CB1 and CB2 receptors in the mouse colon, suggesting a close linkage and cross-talk between the p38MAPK signaling pathway and the endogenous CB system. Baishideng Publishing Group Inc 2016-11-21 2016-11-21 /pmc/articles/PMC5116595/ /pubmed/27920472 http://dx.doi.org/10.3748/wjg.v22.i43.9515 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Basic Study
Feng, Ya-Jing
Li, Yong-Yu
Lin, Xu-Hong
Li, Kun
Cao, Ming-Hua
Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK
title Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK
title_full Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK
title_fullStr Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK
title_full_unstemmed Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK
title_short Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK
title_sort anti-inflammatory effect of cannabinoid agonist win55, 212 on mouse experimental colitis is related to inhibition of p38mapk
topic Basic Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116595/
https://www.ncbi.nlm.nih.gov/pubmed/27920472
http://dx.doi.org/10.3748/wjg.v22.i43.9515
work_keys_str_mv AT fengyajing antiinflammatoryeffectofcannabinoidagonistwin55212onmouseexperimentalcolitisisrelatedtoinhibitionofp38mapk
AT liyongyu antiinflammatoryeffectofcannabinoidagonistwin55212onmouseexperimentalcolitisisrelatedtoinhibitionofp38mapk
AT linxuhong antiinflammatoryeffectofcannabinoidagonistwin55212onmouseexperimentalcolitisisrelatedtoinhibitionofp38mapk
AT likun antiinflammatoryeffectofcannabinoidagonistwin55212onmouseexperimentalcolitisisrelatedtoinhibitionofp38mapk
AT caominghua antiinflammatoryeffectofcannabinoidagonistwin55212onmouseexperimentalcolitisisrelatedtoinhibitionofp38mapk